Table 1.
Main characteristics of the eligible studies
| Author | Country | Year | Method |
Cases |
Controls |
Cutoff of |
Dilution of antibody | Situation of patients | HR |
|---|---|---|---|---|---|---|---|---|---|
| (ALDH1A1 + ) | (ALDH1A1 - ) | ALDH1A1 positive | |||||||
| Ginestier U.M. [11] |
America |
2007 |
IHC (TMA) |
24 |
122 |
> 5% |
BD Biosciences, 1:100 |
NA |
NA |
| Ginestier I.P.C [11] |
France |
2007 |
IHC (TMA) |
102 |
243 |
> 5% |
BD Biosciences, 1:100 |
NA |
1.76 |
| Morimoto [27] |
Japan |
2009 |
IHC |
21 |
182 |
> 0% |
BD Biosciences, 1:100 |
Treated with surgery |
1.516 |
| Charafe-Jauffret [24] |
France |
2010 |
IHC |
29 |
53 |
> 1% |
BD Biosciences, 1:50 |
IBC, partly treated with surgery |
SS, 2.7 |
| MFS, 2.72 | |||||||||
| Erika Resetkova [29] |
America |
2010 |
IHC (TMA) |
35 |
159 |
> 0% |
BD Biosciences, 1:200 |
Treated with surgery |
NA |
| Nalwoga [28] |
Uganda |
2010 |
IHC (TMA) |
88 |
95 |
unclear |
BD Biosciences, 1:250 |
NA |
NA |
| Neumeister [19] |
America |
2010 |
Immunofluorescent assays (AQUA) |
45 |
581 |
NA |
BD Biosciences, 1:1000 |
Treated with surgery |
2.32 |
| Pei Yu [23] |
China |
2010 |
IHC |
18 |
78 |
> 0% |
Abcam, 1:100 |
Treated with surgery |
4.6 |
| He Lee [26] |
Korea |
2011 |
IHC |
12 |
80 |
>5% |
BD Biosciences, 1:100 |
Stage II ~ III, treated with surgery |
4.15 |
| Yasuyo [31] |
Japan |
2011 |
IHC |
54 |
52 |
> 0% |
BD Biosciences, 1:1000 |
TNBC, treated with surgery |
3.696 |
| Yoshioka [32] |
Japan |
2011 |
IHC |
68 |
189 |
> 0% |
BD Biosciences, 1:1000 |
Treated with surgery |
OS, 1.93 |
| RFS, 1.667 | |||||||||
| Mieog [18] |
Netherlands |
2012 |
IHC |
292 |
195 |
> 0% |
BD Biosciences, NA |
Treated with surgery |
RS, 2.36 |
| RFS, 1.71 | |||||||||
| Nogami [21] |
Japan |
2012 |
IHC |
7 |
33 |
> 5% |
BD Biosciences, 1:200 |
ALNM+, treated with surgery |
2.26 |
| Sakakibara [22] |
Japan |
2012 |
IHC |
35 |
80 |
>5% |
BD Biosciences, 1:200 |
ALNM+, treated with surgery |
10.044 |
| Tan [30] |
China, Malay, Indian, Other |
2013 |
IHC |
35 |
106 |
>10% |
Abcam, 1:100 |
Treated with surgery |
NA |
| Dong [25] | China | 2013 | IHC | 56 | 105 | >5% | BD Biosciences, 1:200 | Invasive ductal carcinoma and ALNM+, treated with surgery | OS, 3.309 |
| RFS, 2.774 |
a) IBC was defined as inflammatory breast cancer, it is stage IIIB.
b) TMA was defined as tissue microarrays.
c) AQUA was defined as automated quantitative analysis.
d) TNBC breast cancer was defined as triple-negative breast cancer.
e) ALNM was defined as axillary lymph node metastases, it is ≥ Stage II.